Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analysts rate Telix a "Moderate Buy" — nine analysts cover TLX (1 sell, 1 hold, 6 buy, 1 strong buy) with an average 12‑month price target of about $21.13.
• Shares opened at $11.00, trading between a 12‑month low of $6.28 and high of $18.99, with 50‑ and 200‑day moving averages near $8.95 and $8.78 respectively.
• Recent quarterly results missed expectations: EPS of ($0.01) vs. $0.05 consensus and revenue of $206.72M vs. $421.50M consensus, signaling a significant top‑line shortfall.

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $21.1250.

A number of brokerages recently weighed in on TLX. Wall Street Zen raised shares of Telix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, April 11th. Weiss Ratings reissued a "sell (d)" rating on shares of Telix Pharmaceuticals in a research note on Monday, April 20th. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a report on Monday, January 19th. Wedbush reiterated an "outperform" rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a report on Monday, April 13th. Finally, Citigroup lifted their target price on Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a "buy" rating in a research report on Tuesday, February 24th.

Institutional Trading of Telix Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in TLX. Rhumbline Advisers lifted its position in shares of Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company's stock worth $25,000 after purchasing an additional 1,392 shares in the last quarter. XTX Topco Ltd bought a new position in Telix Pharmaceuticals in the fourth quarter valued at $89,000. IHT Wealth Management LLC acquired a new stake in Telix Pharmaceuticals in the 2nd quarter valued at $213,000. OLD Mission Capital LLC acquired a new stake in Telix Pharmaceuticals in the 4th quarter valued at $111,000. Finally, JPMorgan Chase & Co. bought a new stake in Telix Pharmaceuticals during the 3rd quarter worth about $243,000.

Telix Pharmaceuticals Trading Up 5.5%

Shares of TLX opened at $11.00 on Friday. Telix Pharmaceuticals has a twelve month low of $6.28 and a twelve month high of $18.99. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The firm's 50 day moving average price is $8.95 and its two-hundred day moving average price is $8.78.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) last issued its quarterly earnings data on Friday, February 20th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.06). The firm had revenue of $206.72 million for the quarter, compared to the consensus estimate of $421.50 million. As a group, research analysts forecast that Telix Pharmaceuticals will post 0.09 earnings per share for the current year.

About Telix Pharmaceuticals

Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.